Collective Family Office LLC Gilead Sciences, Inc. Transaction History

Collective Family Office LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 13, 2023	SELL	$73.94 - $80.67 $30,759 - $33,558	-416 Reduced 8.96%	4,226 $316,000
Q2 2023 Jul 12, 2023	BUY	$76.01 - $86.7 $352,838 - $402,461	4,642 New	4,642 $357,000
Q4 2022 Jan 11, 2023	SELL	$62.32 - $89.47 $105,694 - $151,741	-1,696 Reduced 41.34%	2,407 $0
Q3 2022 Oct 14, 2022	SELL	$59.54 - $68.01 $71,448 - $81,612	-1,200 Reduced 22.63%	4,103 $253,000
Q2 2022 Jul 18, 2022	SELL	$57.72 - $65.01 $327,561 - $368,931	-5,675 Reduced 51.69%	5,303 $328,000
Q1 2022 Apr 25, 2022	BUY	$57.92 - $72.58 $201,156 - $252,070	3,473 Added 46.28%	10,978 $653,000
Q4 2021 Jan 18, 2022	SELL	$64.88 - $73.64 $23,810 - $27,025	-367 Reduced 4.66%	7,505 $545,000
Q3 2021 Oct 08, 2021	SELL	$67.69 - $73.03 $42,983 - $46,374	-635 Reduced 7.46%	7,872 $550,000
Q2 2021 Jul 14, 2021	SELL	$63.47 - $69.35 $28,180 - $30,791	-444 Reduced 4.96%	8,507 $586,000
Q1 2021 Apr 14, 2021	SELL	$60.0 - $68.46 $45,000 - $51,344	-750 Reduced 7.73%	8,951 $579,000
Q4 2020 Feb 12, 2021	BUY	$56.65 - $64.55 $549,561 - $626,199	9,701 New	9,701 $565,000

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Collective Family Office LLC, based on Form 13F filings with the SEC.

Stay updated on Collective Family Office LLC with notifications on news.